And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

What Happened: Susi's recent Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday unveiled the sale of 5,000 shares of iRadimed. The total transaction value is $488,316.

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Stevie OReilly, born in Cairns at just 22 weeks and two days and believed to be the most premature baby in Australia ever to ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

Between exiting the Smiths remediation process, leveraging new product introductions (and overhead leverage), and ...

Roger E Susi, CEO at iRadimed (NASDAQ: IRMD ), disclosed an insider sell on December 22, according to a recent SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...